Renal cell carcinoma: Complete response

Anti-Cancer Drugs

Volumn 21, Issue SUPPL.1, 2010, Pages

  Calvo, Ovidio Fernández ^a   Vázquez, Diana Dopico ^a   López, Margarita Reboredo ^a   Aparicio, Luis Miguel Antón ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Complete response; Renal cancer; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LUNG LOBE; LUNG LOBECTOMY; LUNG METASTASIS; LUNG NODULE; MALE; MEDIASTINUM METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; SMOKING; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 76449116947     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000361531.59299.5a     Document Type: Article

References (7)

1. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
2. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
4. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Né grier S, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26 (20 Suppl):abstr 5024.
5. Heng DY, Rini BI, García J, Wood L, Bukowski RM. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007; 5:446-451.
6. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007; 18:1282-1283.
7. Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 2006; 5:232-234.